Published in Antimicrob Agents Chemother on February 01, 2005
Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev (2005) 5.77
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 2.63
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother (2008) 1.43
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother (2006) 1.40
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One (2012) 1.32
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother (2007) 0.98
Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother (2008) 0.98
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother (2009) 0.98
Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother (2012) 0.98
The role of fungi in diseases of the nose and sinuses. Am J Rhinol Allergy (2012) 0.95
Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother (2011) 0.93
Native and modified lactate dehydrogenase expression in a fumaric acid producing isolate Rhizopus oryzae 99-880. Curr Genet (2007) 0.89
Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol (2011) 0.88
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Human fungal pathogens of mucorales and entomophthorales. Cold Spring Harb Perspect Med (2014) 0.82
Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother (2011) 0.81
Biology, systematics, and clinical manifestations of Zygomycota infections. Eur J Clin Microbiol Infect Dis (2014) 0.80
Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc (2010) 0.79
Drug combinations against Mucor irregularis in vitro. Antimicrob Agents Chemother (2013) 0.78
Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature. Case Rep Med (2014) 0.75
How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review. Med Mycol Case Rep (2015) 0.75
Zygomycetes in human disease. Clin Microbiol Rev (2000) 9.80
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother (2003) 2.01
Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol (1997) 1.77
Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B. Laryngoscope (1988) 1.41
Rhinocerebral mucormycosis. J Am Dent Assoc (1977) 1.04
A multiple comparisons sign test: all pairs of treatments. Biometrics (1967) 1.03
Rhinocerebral mucormycosis: a report of eleven cases. Southeast Asian J Trop Med Public Health (1991) 1.01
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog (2006) 3.58
Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol (2007) 3.43
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med (2008) 3.36
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem (2004) 2.77
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 2.63
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother (2005) 2.54
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis (2005) 2.42
Current treatment strategies for disseminated candidiasis. Clin Infect Dis (2005) 2.25
Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2004) 2.23
Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet (2009) 2.15
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother (2003) 2.01
Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother (2006) 1.99
Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis (2010) 1.96
the hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog (2008) 1.94
Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun (2003) 1.78
The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun (2008) 1.77
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 1.77
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis (2006) 1.64
Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect Immun (2004) 1.59
Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry (2004) 1.59
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun (2005) 1.53
Functional analysis of the Candida albicans ALS1 gene product. Yeast (2004) 1.50
Global cell surface conformational shift mediated by a Candida albicans adhesin. Infect Immun (2004) 1.46
Ultrastructural evidence of mitochondrial abnormalities in postresuscitation myocardial dysfunction. Resuscitation (2011) 1.46
Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother (2008) 1.43
Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun (2005) 1.42
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother (2006) 1.40
N-cadherin mediates endocytosis of Candida albicans by endothelial cells. J Biol Chem (2005) 1.36
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun (2005) 1.35
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest (2010) 1.34
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One (2012) 1.32
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol (2010) 1.27
Candida albicans Als proteins mediate aggregation with bacteria and yeasts. Med Mycol (2007) 1.26
A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol (2005) 1.23
Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol (2006) 1.21
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother (2009) 1.21
Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis (2008) 1.15
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Risk factors for mortality in patients with mucormycosis. Med Mycol (2012) 1.13
Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol (2006) 1.11
Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett (2004) 1.11
The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun (2006) 1.10
Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother (2005) 1.09
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother (2009) 1.08
Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol (2009) 1.05
CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest (2013) 1.04